Tick-borne encephalitis virus (TBEV) encodes an abundant, highly immunogenic nonstructural glycoprotein, NS1. The function of this protein has yet to be determined. We have cloned the NSl gene from the Neudorfl strain of TBEV under the control of the powerful constitutive cytomegalovirus major immediate-early promoter into an adenovirus El deletion mutant. The novel combination of the cytomegalovirus immediateearly promoter and the adenovirus vector produced extremely high levels of NS1 expression in cells which do not support replication of the adenovirus deletion mutant. The recombinant protein was shown to be indistinguishable from authentic TBEV NS1 in its (i) apparent molecular weight by polyacrylamide gel electrophoresis, (ii) glycosylation pattern, (iii) ability to form high-molecular-weight complexes, and (iv) ability to be secreted from cells. Appropriate processing of NS1 expressed by the adenovirus recombinant occurred independently of any additional TBEV-encoded gene function. When directly inoculated into mice, the recombinant adenovirus RAd51 was shown to elicit an antibody response to the TBEV NS1 protein.
The Flaviviridae are a family of over 60 arthropod-borne viruses and includes tick-borne encephalitis virus (TBEV), Japanese encephalitis virus (JEV), yellow fever virus, dengue virus, Kunjin virus, and possibly hepatitis C virus. TBEV is transmitted exclusively by ticks and can be divided into two clinically important subtypes on a serological basis: the Eastern subtype (e.g., Sofjin strain), prevalent in far eastern regions of the USSR, and the Central European subtype (e.g., Neudorfl strain), common to eastern and central Europe.
As with other flaviviruses, TBEV has a single-stranded, positive-sense RNA genome (reviewed in reference 3). The nucleotide sequence of both the Neudorfl (18, 19) and Sofijn (25) strains has recently been determined and shows TBEV to encode a single open reading frame for over 3,000 amino acids. By post and cotranslational proteolytic processing, at least three structural and seven nonstructural (NS) proteins are generated from this large precursor. The order of the flavivirus proteins within this long open reading frame from the N terminus is capsid, prematrix, envelope (E), NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5.
Although it is relatively abundant, the biological function of the flavivirus NS1 protein is unknown. NS1 has an apparent molecular weight by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) of between 47 and 51 kDa and exists in both an intracellular and extracellular form (17, 21, 34) . More detailed information is available for other members of the Flaviviridae. The NS1 proteins of JEV, yellow fever virus, and dengue virus, which all have an apparent molecular mass similar to that of TBEV, contain at least two N-linked glycosylation sites (21, 27, 42) . In both TBEV and dengue virus, intracellular NS1 has been shown to be further processed into a larger form, the increase in size being associated with export from the cell (17, 42) . The * Corresponding author. intra-and extracellular forms of NS1 from several flaviviruses, including dengue virus (41) , Powassan virus, St. Louis encephalitis virus (42) , JEV (8) , and yellow fever virus (27, 31) , have been shown to form high-molecular-weight complexes. These complexes have been found to dissociate readily on heating or treatment with low pH (42) . Larger forms of the NS1 protein (NS1'), which have so far only been identified in JEV-and yellow fever virus-infected cells, are believed to contain the entire NS1 protein plus a portion from the adjacent N terminus of NS2A (4, 21) .
During the course of a natural infection, NS1 evokes a strong immune response (36) . Experiments performed with dengue and yellow fever viruses have demonstrated protection to virus challenge in mice and, in the case of yellow fever virus, monkeys immunized with purified NS1 protein (30, 32) or mice passively protected with anti-NS1 monoclonal antibodies (9, 14, 33) . Although anti-NS1 antibodies are unable to neutralize virus infection, they are capable of eliciting complement-mediated cell lysis of virus-infected cells (30, 31) . The role and mechanism of the protective immune response elicited by NS1, while as yet poorly characterized, has important implications for the development of flavivirus vaccines. It has been demonstrated for a number of flaviviruses that antibodies to the E protein can actually enhance the uptake of virus by cells of the monocyte-macrophage lineage (24, 26) . Antibody-dependent enhancement of dengue virus infection has been demonstrated in monkeys (13) . Since the NS1 protein has the potential to elicit a protective immune response while antibodies to the E protein can enhance virus infection, the development of flavivirus vaccines based on nonstructural proteins may be beneficial.
In order to investigate whether an immune response to TBEV NS1 could confer protection against disease, we set out to clone and express the gene in a eukaryotic system. The precise limits to the coding sequence for TBEV NS1 within the polyprotein precursor are not certain. However, the N-terminal amino acid sequence of the mature NS1 protein has been determined for several mosquito-borne flaviviruses (1, 29) . Immediately preceding the amino terminus of NS1 is a translocation signal sequence (6) responsible for targeting glycoproteins into the endoplasmic reticulum during protein synthesis, the translocation signal sequence being cleaved off during maturation of the protein. A putative translocation signal sequence for NS1 is present within the TBEV Neudorfl strain polyprotein between amino acids 2366 and 2440 (19) . Although the C terminus of a mature flavivirus NS1 protein has yet to be identified directly, the N terminus of the downstream protein (NS2A) has been determined for Kunjin virus by direct amino acid sequencing of the purified protein (35) . Amino acid sequence alignment of the TBEV Neudorfl, Sofjin, and K23 strains with Kunjin virus identifies a conserved proteolytic cleavage signal sequence (at amino acid 1128 of the Neudorfl strain). Assuming no overlap or gap between the NS1 and NS2A coding regions, the conserved proteolytic cleavage site also identifies a putative C terminus of TBEV NS1. Eight conserved amino acids at the putative carboxy terminus of NS1 have been shown to be necessary for cleavage at the NS1-NS2A junction of dengue virus (15) . Efficient proteolytic cleavage at the dengue virus NS1-NS2A junction also requires the presence of at least 70% of the NS2A protein (7) .
Experimental data from other flaviviruses was therefore used to predict the positions of both the N and C termini in the mature TBEV NS1 protein and identify additional elements which could be required for efficient expression, i.e., the upstream translocation signal sequence and a functional downstream NS2A protein. We have used a novel adenovirus-based expression system to demonstrate that the TBEV NS1 protein plus only its translocation signal sequence is capable of being efficiently expressed and appropriately processed. Direct vaccination with an adenovirus recombinant expressing NS1 provided protection against lethal challenge with TBEV.
MATERIALS AND METHODS
Cells and viruses. The Neudorfl isolate of TBEV was propagated on porcine kidney (PS) cells as described previously (38) . 293 cells (11) and primary human embryo lung fibroblasts (MRC5 cells) were grown as monolayers in Glasgow's modified Eagle's medium (Imperial Laboratories, Andover, United Kingdom) supplemented with 8% fetal calf serum (Imperial Laboratories) at 37°C. In one experiment, following infection of MRC5 cells, the medium was replaced with serum-free culture medium (PAA, Linz, Austria). The defective adenovirus recombinants were generated and propagated in 293 cells (10) . When grown in nonpermissive MRC5 cells, 10 ,uM forskolin (Sigma, Poole, United Kingdom) was added to stimulate expression from the cytomegalovirus (CMV) immediate-early (IE) promoter in the adenovirus recombinants. The calcium phosphate coprecipitation method was used for all DNA transfections (12, 20) .
Construction of cDNA clones. Standard genetic manipulation techniques were used in the construction of recombinant plasmids (20) , with all enzymes being purchased from the Promega Corporation (Southampton, United Kingdom) unless otherwise stated. Total cytoplasmic RNA was purified from PS cells 48 h postinfection with TBEV (1 PFU/cell), using a phenolchloroform extraction procedure described previously (39) .
RNA (5 ,ug) and random hexameric primers (0.5 jig) ( All DNA sequence coordinates on the TBEV genome follow those used by Mandl and co-workers (19) . A 1,891-bp TBEV cDNA fragment (FENS12A), containing 33% of the 3' end of the E gene, the complete NS1 gene, and 79% of the NS2A gene, was generated in a polymerase chain reaction (PCR) with the oligonucleotide primers P1 and P2 (Fig. 1) .
PCR was performed in a 20-,ul volume containing 4 pl of the product of the reverse transcription reaction, 0.1 ,uM each of both primers, lx PCR buffer, and 1 U of Taq polymerase.
The cDNA template was denatured at 94°C for 45 s, primers were annealed for 2 min at 64°C, and primer extension was performed at 72°C for 2 min. Primer P1 is homologous to 26 bases from nucleotide 2096 on the positive cDNA strand of the TBEV genome, while primer P2 is complementary to 25 bases on the positive cDNA strand ending at nucleotide 3987. Primers P1 and P2 also contain additional 5' sequence elements designed to provide the PCR-generated DNA fragment FENS12A with flanking BglII restriction endonuclease cleavage sites (Fig. 1) . FENS12A was digested with BglII and inserted into the unique BglII site in the plasmid vector pMTL23 (2).
Primers P3, P4, and P5 were used in conjunction with P1 and P2 in PCR experiments to generate five additional shorter DNA fragments with the cloned FENS12A fragment as a template (Fig. 1) . Primers P3 and P5 are homologous to 18 bp on the positive strand from nucleotide 2441 and 2366, respectively. These primers were designed to generate an upstream XbaI site to facilitate cloning and an in-frame translation initiation codon. Primer P4, which is complementary to 21 bp on the positive strand ending at nucleotide 3496, also contains an additional upstream element that generated a translation termination codon (TAA) and an XbaI site during PCR.
Fragments generated by using primer P1 did not contain an in-frame translation initiation codon, and fragments generated by using P2 did not contain an in-frame translation termination codon. This deficiency was remedied by the ligation of the linker Li to the relevant BglII-cleaved fragments during cloning. All the PCR-generated fragments listed in Fig. 1 were inserted into the XbaI site of the vector pMTL23, and the identity of the fragments was confirmed by direct plasmid sequencing.
The cDNA fragments FENS12A, FENS1, FNS1, FNS12A, FSNS1, and FSNS12A were each excised from their respective plasmids (Fig. 1 ) by using the restriction enzyme XbaI and inserted into the transient expression vector pMV100, placing the NS1 gene under the control of the CMV major IE promoter ( Fig. 2A) .
Construction of RAd51. The recombinant adenovirus RAdS1 was generated by the method developed by McGrory and co-workers (23) . The CMV IE promoter-NS1 expression cassette was excised from plasmid pMV45, containing (36) with the aid of an adaptor at its unique XbaI site. The plasmid pJM17 (22) contains the genome of adenovirus type 5 d1309 with the prokaryotic vector pBRX inserted into the Ela gene. The size of pJM17 exceeds the packaging limit for adenovirus particles. Following cotransfection of 293 cells, homologous recombination between pMV51 and pJM17 resulted in insertion of the CMV IE promoter-NS1 expression cassette into the adenovirus vector. As a consequence of recombination, pBRX and the adenovirus El region were deleted, reducing the overall size of the vector and thus permitting packaging of the adenovirus genome (Fig. 2B ). The recombinant virus RAd5l was generated and plaque purified three times. Plasmids pXCX2 and pJM17 were kindly provided by Frank Graham (McMaster University, Hamilton, Ontario, Canada).
Immunofluorescence. Acetone-fixed cells were first incubated with the monoclonal antibody T12 (200 ,ug/ml) (36), washed in phosphate-buffered saline (PBS) for 30 min, and then incubated with fluorescein isothiocyanate-conjugated goat anti-mouse immunoglobulin G (IgG)-PBS (Sigma).
Immunoprecipitation. Cells were grown for 16 h with methionine-free Glasgow's modified Eagle's medium (Imperial Laboratories) prior to the addition of 250 S.Ci of l355]methionine (Amersham) in 1 ml of fresh methionine-free medium. Cells were harvested and resuspended in 0.5 ml of lysis buffer (20 ,ug of phenylmethylsulfonyl fluoride per ml, 25 ,ug of aprotinin per ml, 1% Nonidet P-40, 0.15 M NaCl, 1 mM EDTA, 0.1 M Tris-HCI [pH 7.5]). Nuclei were removed by centrifugation prior to immunoprecipitation. Cell culture supernatants were used directly in immunoprecipitation experiments.
Tissue culture supernatant (0.5 ml) or cell lysate (100 RIl) was reacted for 1 h on ice with a mixture containing equal volumes of the anti-NS1 monoclonal antibodies T12, T17, T33/1, T33/3, and T33/4 (36). Antibody-antigen complexes were captured by incubation for 1 h at 4°C with 1/10 volume of protein A-and protein G-Sepharose beads (Pharmacia) in equal proportions. The Sepharose beads were washed three times with PBS before being added to PAGE sample buffer containing 0.5% 2-mercaptoethanol, boiled for 10 min, and then analyzed by SDS-PAGE (16 (19) . The DNA fragments FENS12a, FENS1, FNS1, FSNS12a, and FSN1 were generated by using the oligonucleotide primers P1 to P5 as indicated. The adaptor Li was self-annealed and ligated to the PCR-generated fragments as indicated to provide either a translational start or stop codon, as appropriate.
RESULTS
Cloning and transient expression of the NS1 gene. Total cytoplasmic RNA purified from TBEV-infected cells was reverse-transcribed by using random primers, and a cDNA fragment containing the complete NS1 gene together with part of the E and NS2A genes (fragment FENS12A) was generated by PCR with primers P1 and P2 (Fig. 1) . Initially, a truncated fragment was produced-with a 0.9-kb deletion which mapped to a region with the potential to encode secondary structure in the corresponding RNA molecule (results not shown). The inclusion of dimethyl sulfoxide in the reverse transcription reaction buffer was necessary for efficient generation of the full-sized cDNA fragment. Fragment FENS12A was cloned, and its nucleotide sequence was determined. The sequence of the cloned fragment was found to be in agreement with published results (18) (Fig. 3B) and pMV54 (fragment FSNS12A). The expressed protein was recognized by three different monoclonal antibodies (T12, T33/1, and T33/3) raised against the NS1 protein, with the cytoplasmic pattern of fluorescence produced being similar to that observed in TBEV-infected cells (Fig. 3C) (Fig. 4a) (Fig. 5, lanes 10 and 11) , while no corresponding protein band was seen in the mock-infected cell lysates (Fig. 5, lanes  1 ). The comigration of the two proteins implies that there are no major differences between the recombinant and the TBEV-encoded NS1 proteins and suggests that the predicted proteolytic cleavage site at the C terminus of NS1 chosen for use in the construction of the adenovirus recombinant is identical, or extremely close, to the one used by TBEV.
During the course of a productive TBEV infection, NS1 is secreted into the supernatant. A 51-kDa protein specifically precipitated from RAd51-infected cell supernatants with anti-NS1 monoclonal antibodies comigrated with the secreted form of NS1 protein produced by cells infected with TBEV (Fig. 5a, lanes 4 and 5) . Thus, the recombinant NS1 is also secreted from infected cells. Both the recombinant and the authentic TBEV extracellular forms of NS1 were consistently found to comigrate on polyacrylamide gels and to be of higher apparent molecular weight than their intracellular counterparts.
Glycosylation of NS1. During its synthesis in infected cells, NS1 is translocated to the lumen of the endoplasmic reticulum, oligomerized, and eventually secreted from the cell. The ability of the NS1 synthesized from the recombinant adenovirus to complete these posttranslational modifications was examined further by a comparison of the susceptibility of recombinant and TBEV-encoded NS1 to digestion with endoH and glycoF. EndoH removes N-linked high-mannose or hybrid oligosaccharide side chains but is ineffective against complex glycans, whereas glycoF cleaves all three types of N-linked glycans.
Treatment with both glycosidases was shown to have a similar effect on the recombinant and TBEV-encoded NS1 proteins as analyzed by SDS-PAGE (Fig. 5) . The presence of N-linked high-mannose or hybrid oligosaccharide side chains on the intracellular forms of NS1 proteins was revealed by endoH digestion, which reduced the apparent size of NS1 by 8 kDa from 47 to 39 kDa (Fig. 5a, lane 12; Fig. Sb,  lanes 1 and 2) . Treatment of intracellular NS1 with glycoF produced a band which comigrated with the endoH-treated form, indicating that no complex or biantennary side chains were present on the intracellular form of the protein (Fig. 5a,  lanes 8 and 9) . The molecular mass of the deglycosylated form of NS1, 39 (lanes 1, 3, 5, 7, 9 , 11, and 13) and culture supernatant (lanes 2, 4, 6, 8, 10, 12, and 14) were obtained at 0 h (samples 1 and 2), 1 h (3 and 4), 2 h (5 and 6), 3 h (7 and 8), 4 h (9 and 10), and 5 h (11 and 12) after the addition of the pulse. Samples 13 and 14 are cell lysate and tissue culture supernatant, respectively, from mock-infected cells pulse-labeled and then incubated for 4 h. All samples were immunoprecipitated with the monoclonal antibody T12 and then subjected to SDS-PAGE, followed by fluorography. Sizes are shown in kilodaltons.
primary amino acid sequence of 39,162 Da predicted from DNA sequence analysis (24) . Unlike the intracellular forms of NS1, treatment of extracellular NS1 (TBEV or RAd51 encoded) with either endoH or glycoF did not generate comigrating proteins (Fig. 5a, lanes 2, 3, 6 , and 7). Untreated extracellular NS1 (Fig. 5a, lanes 4 and 5) migrates more slowly than the corresponding intracellular form on SDS-PAGE (Fig. 5a, lanes 10 and 11; Fig. Sb, lanes 3 and 4) , with an apparent molecular mass of 51 kDa. However, following treatment with glycoF, the extracellular forms comigrate with the treated intracellular forms described above. EndoH treatment of extracellular NS1 generated a protein which migrated with an apparent molecular mass of 47 kDa, not 39 kDa, implying that in going from the intra-to the extracellular form, both the recombinant and the wild-type NS1 proteins acquire additional complex or biantennary oligosaccharide side chains.
Kinetics of expression. A pulse-chase experiment was performed to investigate the kinetics of NS1 synthesis and secretion in RAd51-infected MRC5 cells (Fig. 6) . The autoradiograph was overexposed to show the temporal expression of intracellular NS1; in shorter exposures (not shown), the difference in migration of the intra-and extracellular forms of NS1 can be seen. The intracellular forms of NS1 was detectable 1 h after addition of isotope, reaching a maximum by 3 h, after which the levels declined. Extracellular NS1 protein was detected in RAd51-infected tissue culture supernatant at high levels from 3 h onward. Detection of intracellular prior to the extracellular NS1 is consistent with there being a product-precursor relationship between the two forms of the protein.
Level of NS1 expression from the adenovirus recombinant. The combination of the CMV major IE promoter and the adenovirus Ela vector was chosen as a nonlytic system that was adaptable to a wide variety of cell types. Experiments performed with similar adenovirus recombinants indicated that the system was capable of producing surprisingly high levels of expression (37) . In order to maximize expression levels, MRC5 cells were infected with RAd51 at a very high multiplicity of infection and cultured in the presence of a known stimulator of the CMV IE promoter (forskolin).
FIG. 7.
Tissue culture flasks (175 cm2) of MRC5 cells were infected with either RAd51 or a control adenovirus El-deletion mutant at 100 PFU/cell and then incubated for 6 days in serum-free medium containing 10 FM forskolin. Tissue culture supernatant (1/250 of total sample) and cytoplasmic cell lysate (1/50 of total sample) were subjected to SDS-PAGE on a S to 15% polyacrylamide gradient gel. Lanes: 1 and 8, adenovirus E1--infected cell lysate; 2 and 7, adenovirus El--infected cell supernatant; 3 and 6, RAd5l-infected cell supernatant; 4 and 5, RAd5l-infected cell lysate. Samples 5 to 8 only were heat denatured prior to electrophoresis.
Bands attributed to the NS1 protein are indicated with arrowheads. Sizes are shown in kilodaltons.
Samples prepared from infected-cell lysates and tissue culture supernatant were subjected to SDS-PAGE, followed by direct Coomassie blue staining of the gel (Fig. 7) . In samples that were heat treated prior to electrophoresis, the gel clearly shows the presence of an infected-cell-specific protein (ICSP) with an apparent molecular mass of 47 kDa in cell extracts (lane 5), which comigrates with a less abundant cellular protein and a slightly bigger ICSP of approximately 51 kDa present in the supernatant (lane 6). These ICSPs are interpreted as representing the intra-and extracellular forms of NS1. In samples that were not boiled prior to electrophoresis, neither protein band is visible, but additional slower bands are apparent, which presumably correspond to NS1 protein complexes (lanes 3 and 4) . Interestingly, in the unboiled samples, the extracellular protein complex migrates faster than the intracellular protein complex. This anomaly may be due to some conformational property of the oligomerized protein.
The NS1 protein was identified as the predominant cytoplasmic protein in RAd51-infected cells, whereas NS1 cannot be visualized on similarly stained gels in extracts from TBEV-infected cells (not shown). The level of NS1 expression observed by using the adenovirus recombinant exceeds the yields obtained from TBEV-infected cultures.
Murine protection studies. The ability of the recombinant adenovirus expressing NS1 to protect against lethal peripheral virus challenge was tested in a mouse protection model. Preliminary experiments demonstrated that the adenovirus recombinant RAd35 could express ,-galactosidase, under the control of the CMV IE promoter, when infected into primary murine macrophage cultures. It was therefore decided to attempt to inoculate the mice directly with RAd51 rather than to purify the recombinant NS1 protein. Such is the yield of NS1 in RAd51-infected cultures that the RAd51 inoculum given to the mice inevitably did contain some NS1 protein. In a pilot experiment, mice were inoculated with RAd51 according to the prescribed schedule, and sera were assayed in a Western transfer experiment, which demonstrated the presence of antibody which recognized the TBEV NS1 protein (Fig. 4b) . Interestingly, the polyclonal antibody raised against RAd51-encoded NS1 preferentially recognized the mature "dimeric" rather than the immature monomeric form of the protein.
The ability of the adenovirus recombinant to protect against lethal peripheral challenge was tested in the mouse protection model (Table 1) . No mouse receiving a challenge dose of TBEV following inoculation with PBS or the adenovirus recombinant expressing ,3-galactosidase survived. However, the majority of animals vaccinated with RAd51 survived a severe virus challenge, and none of these mice exhibited any symptoms of disease. Those mice that were vaccinated with RAd51 but succumbed still survived longer than the control mice but ultimately exhibited similar symptoms of disease. There was no significant difference in survival time between the controls inoculated with PBS or RAd35, nor did the size of the TBEV challenge dose either significantly effect survival time or, in the case of the RAd51-vaccinated mice, the survival rate.
DISCUSSION
The CMV major IE promoter in a defective adenovirus vector was used to drive high-level expression of the TBEV NS1 gene product in a nonlytic system. Expression was dependent on correctly identifying the coding sequence of the NS1 protein together with its associated processing signals within the large polyprotein which constitutes the primary translation product of the TBEV genome. Five plasmids containing different forms of the NS1 gene cloned under the control of the CMV IE promoter were tested in transient DNA transfection experiments, of which two were shown in immunofluorescence experiments to induce expression of NS1 antigens. Efficient expression was dependent on appropriate presentation of the hydrophobic domain immediately preceding the predicted N terminus of NS1, which is presumed to act as a translocation signal sequence. Recently, analogous translocation signal sequences have been found to be required for expression of the dengue virus and JEV NS1 proteins (6, 8) . It is not clear why the internal translocation signal sequence in the longer fragments FENS1 and FENS12a was not sufficient to permit expression; possibly, the signal sequence was masked by chain folding and thus rendered nonfunctional. The requirement for appropriate processing of the C terminus of NS1 was circumvented in the construct cloned into the adenovirus vector by the insertion of a translational stop codon at the predicted proteolytic cleavage site; a similar strategy has been used successfully to gain expression of JEV NS1 (22) .
Detailed comparison was made between NS1 produced by TBEV and the recombinant adenovirus. NS1 is known to be a glycoprotein secreted from TBEV-infected cells (17) . Both the intracellular and secreted extracellular forms of the recombinant protein comigrated on SDS-PAGE with their TBEV-encoded counterparts. The ends of the NS1 coding sequence must therefore be either identical or extremely close to those used in the generation of the expressed construct (fragment FSNS1). The results of a pulse-chase experiment were consistent with the recombinant intracellular form of TBEV NS1 being a precursor of the slightly larger extracellular form, as also appears to be the case in TBEVinfected cells (17; this study). NS1 contains three potential N-linked glycosylation sites (19) . Endoglycosidase treatment demonstrated the presence of similar N-linked mannose-rich (or hybrid) oligosaccharide side chains on both the recombinant and TBEV-encoded intracellular forms of the protein.
The larger extracellular NS1 (both TBEV and RAd51 encoded), however, contains at least one mannose-rich (or hybrid) and one complex side chain, indicating that an additional glycosylation step is associated with the protein's maturation from the intracellular to the extracellular form. A similar pattern of glycosylation has been observed in dengue virus, for which it has been proposed that intracellular NS1 containing two mannose-rich oligosaccharide side chains remains associated with the Golgi complex until one of the side chains is further processed to a complex-type structure, at which point it is released from the cell (42) .
We clearly demonstrated that the intracellular and extracellular forms of NS1 from both TBEV-and RAd51-infected cells participate in the formation of higher-molecular-weight complexes which survive SDS-PAGE but are sensitive to heat denaturation. In view of the fact that the high level of expression from the recombinant NS1 may be expected to saturate an interaction with any cellular components, it seems probable that these high-molecular-weight complexes represent NS1 homodimers; however, this question was not formally addressed. Similar heat-sensitive complexes ("dimers") have also been identified for the NS1 proteins of dengue virus (42), yellow fever virus (28) , and JEV (8) . There are clear similarities between TBEV and mosquitoborne flaviviruses in the way their NS1 proteins are processed from the polyprotein precursor, glycosylated, assembled into multimeric complexes, and secreted from infected cells, which may reflect a conservation of function. The ability to express high levels of NS1 in a nonlytic system will assist in eliciting the function of the NS1 by permitting the construction of TBEV NS1 mutants and by facilitating biological and biophysical studies on the protein, which can now be produced under lower levels of biological containment.
The primary purpose in expressing recombinant TBEV NS1 was to obtain the protein in a form guaranteed to be free of all other TBEV-encoded proteins for use in animal protection studies. For the mosquito-borne yellow fever and dengue flaviviruses, both causative agents of hemorrhagic diseases, it has been established in mice that an immune response to the NS1 protein, raised either to purified NS1 protein or by passive protection with monoclonal antibodies, confers a degree of protection against lethal challenge with homologous virus (14, 30, 32, 33 Vaccination with RAd5l was demonstrated to protect mice against a high challenge dose of TBEV. Vaccination with RAd51 produced a strong humoral response that is presumed to be raised against de novo-synthesized NS1 in the mouse, although a response to small amounts of NS1 contaminating the RAd5l inoculum could not be ruled out. This novel adenovirus vector-CMV IE promoter combination has not only proved its worth as a high-level expression system, but demonstrated significant potential for use in vaccine development, for which, as a nonreplicative system, it has distinct advantages over current vaccinia virus-based vectors.
The monoclonal antibody T12, which was raised against formaldehyde-fixed antigen (36) , preferentially recognized the immature monomeric form associated with TBEV-infected cells. Monomeric NS1 was not detected in RAD51-infected cells, indicating that the recombinant protein was being processed more efficiently into high-molecular-weight complexes than TBEV-encoded NS1. In contrast to the monoclonal antibody, the polyclonal antibody raised in RAd5l-vaccinated mice had a higher avidity to the mature oligomerized form of NS1 than to the monomer. This result is interpreted as a further indication that the recombinant NS1 is being expressed in a native form.
While vaccination did not protect 100% of the mice against challenge with TBEV, it is possible that higher levels of protection may be attained by reducing the challenge dose. The high TBEV challenge dose may be overcoming immunization in a proportion of the mice, but somewhat surprisingly, a similar survival rate was observed in mice challenged with 100 and 1,000 LD50 doses. Antibody-dependent cell lysis of infected cells is currently accepted as the most satisfactory mechanism to explain the protection elicited by antibodies to NS1. This model is based primarily on the observation that complement-fixing monoclonal antibodies to yellow fever virus NS1 can partially protect mice against virus challenge (13, 32) . Since vaccination with RAd51 would be expected to induce both cellular and humoral responses, our experiments do not provide further insight into the mechanism of protection. However, we did observe in the murine model that RAd5l-induced antibodies to NS1 had significant levels of complement-fixing activity and no detectable virus neutralization activity in vitro (results not shown). The recombinant adenovirus RAd51 will facilitate future studies into the immunological basis for the protection elicited by TBEV NS1 expression and into whether the observed protection is against infection or clinical disease. The protection provided by the recombinant TBEV NS1 protein has clear implications for flavivirus vaccine development programs, as it demonstrates that NS1 can protect without inducing potential enhancing antibodies.
